kabutan

STELLA PHARMA, First Half Net Income Loss Widens, Jul-Sep Net Income Loss Widens

Thu Nov 13, 2025 2:00 pm JST Earnings

4888 STELLA PHARMA CORPORATION 【J-GAAP】

Earnings Report

STELLA PHARMA CORPORATION <4888> [TSE Growth] announced its financial results in the afternoon session on November 13th (14:00). The net loss (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2026 (April to September) expanded to a loss of 307 million yen (compared to a loss of 268 million yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the net income/loss for the October to March period (second half) is expected to turn into a loss of 604 million yen (compared to a profit of 128 million yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the net loss expanded to a loss of 151 million yen (compared to a loss of 107 million yen in the same period last year). The operating profit/loss margin drastically worsened from -95.4% in the same period last year to -136.1%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 153 -301 -303 -305 -10.0 ー Nov 9, 2023 J-GAAP
Apr - Sep, 2024 169 -269 -267 -268 -8.2 ー Nov 8, 2024 J-GAAP
Apr - Sep, 2025 200 -298 -306 -307 -9.1 ー Nov 13, 2025 J-GAAP
YoY +18.3% -10.8% -14.6% -14.6% -10.2%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 9, 2025 J-GAAP
Apr - Sep, 2025 Results 200 -298 -306 -307 -9.1 0 Nov 13, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 792 179 130 128 3.9 0 May 9, 2025 J-GAAP
Oct - Mar, 2025 Guidance 177 -624 -602 -604 -17.8 0 Nov 13, 2025 J-GAAP
YoY -77.7% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 269 -760 -760 -763 -24.7 0 May 10, 2024 J-GAAP
Mar, 2025 961 -90 -137 -140 -4.2 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 377 -922 -908 -911 -26.8 0 Oct 14, 2025 J-GAAP
YoY -60.8% -924.4% -562.8% -550.7% -534.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 108 -103 -106 -107 -3.3 -95.4 Nov 8, 2024 J-GAAP
Oct - Dec, 2024 85 -106 -104 -105 -3.2 -124.7 Feb 12, 2025 J-GAAP
Jan - Mar, 2025 707 285 234 233 7.0 40.3 May 9, 2025 J-GAAP
Apr - Jun, 2025 92 -151 -155 -156 -4.6 -164.1 Aug 7, 2025 J-GAAP
Jul - Sep, 2025 108 -147 -151 -151 -4.5 -136.1 Nov 13, 2025 J-GAAP
YoY 0.0% -42.7% -42.5% -41.1% -35.7%

Related Articles